Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barr syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics, Plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT HIGHLIGHTS STRATEGIC WHITEHAWK COLLABORATION, ACCELERATING INDUSTRY VALIDATION OF NOVEL ADC PAYLOADS, AND AKARI'S DIFFERENTIATED PH1 PLATFORM

AKARI THERAPEUTICS CEO EXPLAINS WHY GROWING INDUSTRY DEMAND FOR NEXT-GENERATION ADC PAYLOADS POSITIONS THE COMPANY AT THE CENTER OF A MAJOR ONCOLOGY OPPORTUNITY

TAMPA, FLA. AND LONDON, JULY 21, 2026 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING ANTIBODY DRUG CONJUGATES (ADCS) WITH NOVEL RNA SPLICING MODULATOR PAYLOADS, TODAY ANNOUNCED A STRATEGIC RESEARCH COLLABORATION WITH WHITEHAWK THERAPEUTICS, A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DEVELOP IMPROVED ADCCANCER TREATMENTS.

AKARI THERAPEUTICS ENTERS STRATEGIC RESEARCH COLLABORATION WITH WHITEHAWK THERAPEUTICS

GLOBALLY RECOGNIZED LEADER IN EARLY-PHASE ONCOLOGY CLINICAL DEVELOPMENT AND EXPERIMENTAL THERAPEUTICS STRENGTHENS STRATEGIC EXPERTISE AS AKARI ADVANCES ITS NOVEL ADC PAYLOAD THAT MODULATES RNA SPLICING INTO FUTURE PHASE 1 FIRST-IN-HUMAN TRIAL TAMPA, FLA. AND LONDON, JULY 07, 2026 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING ANTIBODY DRUG CONJUGATES (ADCS) WITH NOVEL RNA SPLICING MODULATOR PAYLOADS, TODAY ANNOUNCED THE APPOINTMENT OF PATRICIA LORUSSO, D.O.

AKARI THERAPEUTICS APPOINTS FORMER AACR PRESIDENT AND RENOWNED ONCOLOGY DRUG DEVELOPMENT LEADER, PATRICIA LORUSSO, D.O., TO SCIENTIFIC ADVISORY BOARD

CONSOLIDATED CLOSING OF RECENTLY ANNOUNCED $5.5 MILLION PIPE LED BY EXISTING INVESTORS, COMBINED WITH AN ADDITIONAL $2.8 MILLION IN PROCEEDS FROM WARRANT EXERCISES, RESULTS IN APPROXIMATELY $8.3 MILLION OF CAPITAL RECEIVED IN Q2 2026, SUPPORTING FUTURE POTENTIAL VALUE INFLECTION POINTS CONSOLIDATED CLOSING OF RECENTLY ANNOUNCED $5.5 MILLION PIPE LED BY EXISTING INVESTORS, COMBINED WITH AN ADDITIONAL $2.8 MILLION IN PROCEEDS FROM WARRANT EXERCISES, RESULTS IN APPROXIMATELY $8.3 MILLION OF CAPITAL RECEIVED IN Q2 2026, SUPPORTING FUTURE POTENTIAL VALUE INFLECTION POINTS

AKARI THERAPEUTICS COMPLETES PREVIOUSLY ANNOUNCED PIPE, STRENGTHENING BALANCE SHEET AHEAD OF POTENTIAL KEY CLINICAL AND REGULATORY MILESTONES

DISCUSSION HIGHLIGHTS GROWING IMPORTANCE ON NOVEL ADC PAYLOADS, AND AKARI'S ASCO DATA IN KRAS-DRIVEN CANCERS AND FUTURE POTENTIAL

AKARI THERAPEUTICS RELEASES CEO CORNER REFLECTING ON EVOLVING ADC LANDSCAPE AND AKARI'S DIFFERENTIATED PH1 PAYLOAD PLATFORM FOLLOWING ASCO 2026

CEO ABIZER GASLIGHTWALA HIGHLIGHTS PROMISING ASCO DATA DEMONSTRATING SYNERGY OF AKTX-101 WITH ADAGASRIB IN KRAS-DRIVEN CANCERS WATCH THE WHAT THIS MEANS VIDEO HERE TAMPA, FLA. AND LONDON, MAY 28, 2026 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING ANTIBODY DRUG CONJUGATES (ADCS) WITH NOVEL RNA SPLICING MODULATOR PAYLOADS, TODAY ANNOUNCED THAT ITS CEO PARTICIPATED IN A VIRTUAL INVESTOR WHAT THIS MEANS INTERVIEW FOCUSED ON THE COMPANY'S RECENTLY ACCEPTED ABSTRACT AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING.

AKARI THERAPEUTICS DISCUSSES BREAKTHROUGH POTENTIAL OF AKTX-101 AND NOVEL SPLICEOSOME-MODULATING ADC PLATFORM IN VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT FOLLOWING ASCO ABSTRACT ACCEPTANCE

AN ADC WITH A NOVEL RNA SPLICEOSOME MODULATING PAYLOAD PH1 PAIRED WITH A KRAS INHIBITOR DEMONSTRATES SYNERGISTIC CYTOTOXIC ACTIVITY AGAINST KRAS G12D AND G12C- DRIVEN PANCREATIC CANCER MODELS DATA SUPPORTS THE BROADER APPLICABILITY OF TARGETING RNA SPLICING TO ATTACK DIFFICULT-TO-TREAT KRAS-DRIVEN CANCERS

AKARI THERAPEUTICS REPORTS BREAKTHROUGH PRECLINICAL DATA DEMONSTRATING SYNERGISTIC ACTIVITY OF AKTX-101 WITH KRAS INHIBITION IN KRAS-MUTATED PANCREATIC CANCER MODELS

TAMPA, FLA. AND LONDON, MAY 21, 2026 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING ANTIBODY DRUG CONJUGATES (ADCS) WITH A NOVEL RNA SPLICING MODULATOR PAYLOAD, TODAY ANNOUNCED THE SUCCESSFUL PRICING OF A PRIVATE PLACEMENT FINANCING ROUND. THIS TRANSACTION IS EXPECTED TO RAISE AN AGGREGATE OF APPROXIMATELY $5.5 MILLION IN GROSS PROCEEDS. WITH THESE FUNDS THE COMPANY WILL FOCUS ON ADVANCING ITS LEAD ADC PROGRAM UTILIZING ITS UNIQUE RNA SPLICING MODULATOR PAYLOAD, AKTX-101, TOWARD A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL.

AKARI THERAPEUTICS ANNOUNCES $5.5 MILLION PRIVATE PLACEMENT OFFERING

LIVE WEBCAST FIRESIDE CHAT WITH ABIZER GASLIGHTWALA, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ON WEDNESDAY, MAY 20, 2026

AKARI THERAPEUTICS TO PRESENT AT A.G.P.'S ANNUAL HEALTHCARE COMPANY SHOWCASE

PATENT REINFORCES STRATEGIC FOUNDATION FOR LEAD ADC AKTX-101 AND EXPANDING ADC PIPELINE TO NEW MOLECULES TARGETING HIGH-VALUE ONCOLOGY INDICATIONS PATENT REINFORCES STRATEGIC FOUNDATION FOR LEAD ADC AKTX-101 AND EXPANDING ADC PIPELINE TO NEW MOLECULES TARGETING HIGH-VALUE ONCOLOGY INDICATIONS

AKARI THERAPEUTICS SECURES KEY EUROPEAN PATENT FOR ITS NOVEL RNA SPLICING MODULATOR ADC PAYLOAD, STRENGTHENING GLOBAL IP ESTATE FOR ALL MAJOR GLOBAL MARKETS

Akari Therapeutics, Plc

AKTX

Price

Financial Reports

No items found.

Press Releases

Akari Therapeutics, Plc

AKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AKTX